VitamFero, a biotech firm in the Genopole® cluster with a secondary facility in Tours (Indre & Loire) and a developer of novel vaccines, initially veterinary, to prevent specific parasitic diseases, announces its winning of the Indre & Loire Top Companies 2011 trophy for Best Innovation. Thus, VitamFero once again receives recognition for the quality of its R&D programs and its strong growth and economic development (...)
Genopole®’s acknowledged expertise in creating biotech start-ups and providing them with business support is attracting training requests from bioclusters outside France. From February 13-24, Genopole® (France’s leading biopark) will coordinate a training course for eight members of the life science cluster at Jagellonne University, Krakow (Poland). The training is part of a collaboration agreement between the two clusters signed in 2008 and is funded by a European Union (...)
The Genopole®-accredited INSERM/University of Evry " Integrated Biology Unit for Adaptations to Exercise " (UBIAE) - headed by Véronique Billat and specializing in the optimization of motor performance - is developing a scientifically-based training program for local 33-year-old 2008 IKF world heavyweight Thai kickboxing champion Patrice Quarteron (6’2", 260 lb.). The goal is to prepare him for the world kick-boxing championships (starting on March 24 at the Arènes de l’Agora venue in (...)
This second round of funding was lead by the Pradeyrol Development family office along with the private equity fund Fa Dièse, the FRCI, and the historical investors managed by CapDecisif Management. This capital increase will allow InnaVirVax to conduct the Phase I/IIa clinical trial of the VAC-3S immunotherapy in HIV-1 infected patients.
Gene Signal announced the publication of data demonstrating the significant activity of aganirsen (GS-101, eye drop) in two important models of retinal neovascular disease, wet age-related macular degeneration (AMD) and ischemic retinopathy.
On March 2nd, 2012, after its pioneering partnership with the Chinese biopark Biolake, Genopole had the pleasure of welcoming a Chinese delegation, led by Mr. Zhang Tong, Vice-Governor of Hubei, for the signature of a partnership agreement with the French export promotion agency UbiFrance.
This Phase I/IIa trial aims to evaluate the safety and immunogenicity of VAC-3S in patients infected with HIV-1 receiving antiretroviral therapy The first patients have been enrolled in two AP-HP Paris Hospitals This trial is supported by a grant from the “OSEO” French Innovation Agency
The ARISk™ Test Screens Children in Multiplex Families As Early As Six Months by Looking at 65 Genetic Markers Associated With Autism, Paving Way for Early Intervention and Best Outcomes
Global Bioenergies, an industrial biology company developing sustainable routes to light olefins, announces significant progress in the development of its process for the production of biological isobutene. The company confirms its industrialization schedule, with plans for a laboratory-scale pilot as early as mid-2012, an industrial-scale pilot in 2013-2014 and the production of thousands of tons of biological isobutene from 2017 (...)
In collaboration with its partners and under the auspices of the French Ministry of Higher Education and Research and the Ministry of Ecology, Genopole® is organizing the second edition of its competition for innovative biotech business startup plans focused on the environment, agronomy and industry. The competition is intended for those who have an innovative project or business idea that they wish to develop and industrialize. Genopole®, located in greater Paris, is the first French (...)